Document is current

Article History

Received: 21 July 2020

Accepted: 16 November 2020

First Online: 9 January 2021

Compliance with ethical standards

:

: Portions of the salaries of Drs. Hale, Cheatham, and Kurtzberg, were paid by a grant to Duke University from Enzyvant Therapeutics GmbH, which has licensed technology from Duke University for preparing cultured postnatal human thymus for implantation into patients with congenital athymia and for the use of the biomarkers described in this manuscript. It is possible that Duke University and some of the authors may benefit financially if this technology is commercially successful in the future.

: The majority of human thymus tissues studied were obtained anonymously as discarded tissue, which was determined by the Institutional Review Board (IRB) of Duke University Medical Center to not constitute human subjects research and to be exempt from IRB review. Some tissues were obtained under informed consent.

: Written informed consent was provided by the parent(s) of some infants to allow any thymic tissue that was removed and otherwise would be discarded to be potentially used for research. The use of this anonymized consented discarded tissue was approved by the IRB of Duke University Medical Center (Pro001030).

: Not applicable.

:

: None of these funding sources had a role in the decision to publish or determining the content of this publication.